Based on these clues, SNS-targeted anti-obesity agents that increase the resting metabolic rate or thermogenesis in adipose tissues by enhancing β3-AR signaling have been the subjects of ongoing investigations over the past 20 years. The gene discussed is ADRB3; the disease is obesity due to melanocortin 4 receptor deficiency.